Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
The approval was based on efficacy and safety data from 2 prospective clinical trials.
Germline testing advised for metastatic disease, family history suggestive of hereditary disease
Men who had ever used spironolactone had decreased odds of prostate cancer compared with never-users, according to a study.
Three major medical organizations have issued recommendations for the diagnosis and treatment of advanced prostate cancer, including metastatic hormone-sensitive disease and nonmetastatic and metastatic castration-resistant disease.
And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer.
The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
The FDA has granted accelerated approval to Rubraca for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Statin use alone or in combination with metformin tied to lower all-cause, prostate cancer mortality.